Ranbaxy launches Storvas:generic version of Atorvastatin in Malaysia

Mumbai, Sep 27 (UNI) Ranbaxy Malaysia Sdn Bhd.(RMSB), the wholly owned subsidiary of Ranbaxy Laboratories today announced the launch of the first generic version of Atorvastatin, under the brand name 'Storvas', in Malaysia.

Ranbaxy informed the Bombay Stock Exchanged that the product introduced on-day-one, will be made available through all major GP's (General Practitioners), Pharmacies and Hospitals in Malaysia.

Storvas will be sold in dosage forms of 10mg, 20mg and 40mg.

Earlier in July, RMSB became the first company to receive approvals to market generic Oseltamavir and was awarded a contract for supply to the Malaysian government.

The product marketed under the brand name, Fluhalt, is an antiviral used for treatment of H5N1 virus and is available in dosage form of 75 mg capsules. Fluhalt is being supplied to all government hospitals, clinics and pharmacies in Malaysia.

''Ranbaxy is proud to be the first Company to launch the generic alternatives of Atorvastatin and Oseltamivir in Malaysia. It is our constant endeavor to offer affordable and safe generics of high quality to the patients in Malaysia and provide support to the government's healthcare plan,'' Managing Director of RMSB Mr T Jeyabalan observed.

The company has received approvals from the Drugs Control Authority of Malaysia to manufacture and market the products, which are being produced at the company's facility in Malaysia.

The Statin market in Malaysia is estimated at RM 100 mil1ion and is growing at a rate of 25 per cent per annum while Oseltamivir supplies are largely made through the government to meet any emergency threats from bird-flu.

UNI SN WD AW1632